These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 1972852)

  • 21. Measurement of C3 conversion by ELISA estimation of neo-determinants on the C3d moiety.
    Holmskov-Nielsen U; Jensenius JC; Teisner B; Erb K
    J Immunol Methods; 1986 Nov; 94(1-2):1-6. PubMed ID: 2431062
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Plasma C3d/C3 quotient as a parameter for in vivo complement activation.
    Nürnberger W; Bhakdi S
    J Immunol Methods; 1984 Nov; 74(1):87-91. PubMed ID: 6334115
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interaction of fibronectin with complement component C3.
    Hautanen A; Keski-Oja J
    Scand J Immunol; 1983 Mar; 17(3):225-30. PubMed ID: 6402811
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cleavage of the complement system C3 component by HIV-1 proteinase.
    Kisselev AF; Mentele R; von der Helm K
    Biol Chem; 1997 May; 378(5):439-42. PubMed ID: 9191031
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Direct quantitation of activated C3 in human plasma with monoclonal anti-iC3b-C3d-neoantigen.
    Kanayama Y; Kurata Y; McMillan R; Tamerius JD; Negoro N; Curd JG
    J Immunol Methods; 1986 Apr; 88(1):33-6. PubMed ID: 2420896
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A flow cytometric assay for measuring complement receptor 1 (CR1) and the complement fragments C3d and C4d on erythrocytes.
    Freysdottir J; Sigfusson A
    J Immunol Methods; 1991 Aug; 142(1):45-52. PubMed ID: 1833467
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Cleavage fragments of C3 and of dermo-epidermal junction of normal human skin].
    Basset-Séguin N; Yancey KB
    Ann Dermatol Venereol; 1992; 119(9):629-34. PubMed ID: 1285586
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sensitivity and specificity of plasma and urine complement split products as indicators of lupus disease activity.
    Manzi S; Rairie JE; Carpenter AB; Kelly RH; Jagarlapudi SP; Sereika SM; Medsger TA; Ramsey-Goldman R
    Arthritis Rheum; 1996 Jul; 39(7):1178-88. PubMed ID: 8670328
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Circulating C3, C4, and C3 split products (C3c and C3d) during normal pregnancy.
    Teisner B; Hau J; Tucker M; Lahood J; Grudzinskas JG
    Am J Reprod Immunol (1980); 1982 Dec; 2(6):309-11. PubMed ID: 6984294
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mapping the Complement Factor H-Related Protein 1 (CFHR1):C3b/C3d Interactions.
    Hannan JP; Laskowski J; Thurman JM; Hageman GS; Holers VM
    PLoS One; 2016; 11(11):e0166200. PubMed ID: 27814381
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Assay of membrane complement receptors (CR1 and CR2) with C3b- and C3d-coated fluorescent microspheres.
    Lambris JD; Ross GD
    J Immunol; 1982 Jan; 128(1):186-9. PubMed ID: 7033372
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immune complexes in preeclampsia and normal pregnancy.
    Massobrio M; Benedetto C; Bertini E; Tetta C; Camussi G
    Am J Obstet Gynecol; 1985 Jul; 152(5):578-83. PubMed ID: 3893134
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Influence of C3 level on the determination of C3d in plasma and synovial fluid by radial immunodiffusion.
    Hack CE; Paardekooper J; Hannema AJ
    J Immunol Methods; 1986 Feb; 86(2):191-8. PubMed ID: 3080529
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Detection of a neoantigen on human C3bi and C3d by monoclonal antibody.
    Tamerius JD; Pangburn MK; Müller-Eberhard HJ
    J Immunol; 1985 Sep; 135(3):2015-9. PubMed ID: 2410510
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Early- and late-phase activation of complement evaluated by plasma levels of C3d,g and the terminal complement complex.
    Mollnes TE
    Complement; 1985; 2(2-3):156-64. PubMed ID: 3878764
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development and clinical application of electroimmunoassays for the direct quantification of the complement C3 split products C3c and C3d.
    Brandslund I; Teisner B; Hyltoft Petersen P; Svehag SE
    Scand J Clin Lab Invest Suppl; 1984; 168():57-73. PubMed ID: 6333715
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A knowledge-based system for automatic interpretation of an analytical profile of complement factors.
    Wiener F; Groth T; Nilsson U
    J Clin Lab Anal; 1989; 3(5):287-95. PubMed ID: 2809879
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Complement activation in bronchial asthma evaluated by the C3d/C3 index.
    Michel O; Sergysels R; Duchateau J
    Ann Allergy; 1986 Dec; 57(6):405-8. PubMed ID: 3491553
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunohistochemical localization of C3d fragment of complement and S-protein (vitronectin) in normal and diseased human kidneys: association with the C5b-9 complex and vitronectin receptor.
    Okada M; Yoshioka K; Takemura T; Akano N; Aya N; Murakami K; Maki S
    Virchows Arch A Pathol Anat Histopathol; 1993; 422(5):367-73. PubMed ID: 8322453
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cleavage of membrane bound C3bi, an intermediate of the third component of complement, to C3c and C3d-like fragments by crude leucocyte lysosomal lysates and purified leucocyte elastase.
    Carlo JR; Spitznagel JK; Studer EJ; Conrad DH; Ruddy S
    Immunology; 1981 Oct; 44(2):381-91. PubMed ID: 7028603
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.